Development of Selective Aspartic Protease Inhibitors
The aim of the project is to develop selective aspartic protease – plasmepsin inhibitors that are potential malaria therapeutic agents. A new product that inhibits the life cycle of malaria with a new mechanism of action is much needed due to the rapidly growing global malaria resistance that has affected practically all currently used therapeutics. To accomplish the project’s goals an interdisciplinary study will be carried out combining several scientific fields: physical methods, biotechnology, medicinal chemistry and organic chemistry. The following activities will be performed within the framework of the project: 1) research involving a fragment based approach in the discovery of new highly active and selective inhibitors of malaria aspartic proteases-plasmepsins. Increased research efforts will be devoted to the development of cost effective and environmentally friendly synthesis methods of aspartic protease inhibitors to facilitate the evolvement of plasmepsin inhibitors into malaria therapeutic agents for patients with low paying capacity; 2) public availability of the research results that will be published in 6 scientific articles in SCI journals; 3) fixation of industrial property rights with 1 international PCT patent. The project will be carried out in collaboration with Asla Biotech. Planned total implementation time of the project: 36 months. Planned referable costs of the project are LVL 491 962. The project is co-financed by the European Regional Development Fund.
Design of Inhibitors of Zinc Containing Enzymes and Investigation of Anti-Cancer Activity
The new multidisciplinary team has been established for the development of new patent-free anti-cancer agents based on innovative approach to use as pharmacological target zinc containing enzymes (ZCE). The aim of the project is to develop inhibitors of ZCE. This approach is widely recognised during last decade as a promising approach for the development of new anti-cancer agents for the treatment of tumours. In order to decrease the cost of development of new drugs as well as save natural resources the project also involves development of green chemistry and development of alternative methods for biological screening. For the efficient implementation of the project the team unites scientists from several scientific fields – mathematics and computer science, physics, chemistry, biology and pharmacology. Total cost of the project – LVL 1 392 159. The research project will be completed by November 30, 2012. The project is co-financed by the European Social Fund (ESF).
2018 Latvian Institute of Organic Synthesis